Clinical trials: Real World Study
Non-small Lung Cancer
Real-world Study of Taletrectinib in Advanced ROS1+ NSCLC Following Entrectinib Progression
This is a multicenter, non-interventional, observational real-world study to evaluate the efficacy and safety of Taletrectinib in ROS1-positive non-small cell lung cancer (NSCLC) following Entrectinib progression.
- Trial name
- NCT07199010
- Testing
- Taletrectinib
- Where
- China
- Volunteers
- 50 people
- Sponsor
- Innovent Biologics (Suzhou) Co. Ltd.
Vulvar Atrophy, Vulvovaginal Signs and Symptoms
Retrospective Cohort Study of Symptoms and Quality of Life in Women With Genitourinary Syndrome of Menopause.
The goal of this clinical trial is to retrospectively identify the most prevalent symptoms of genitourinary syndrome of menopause (GSM) among postmenopausal women and to evaluate their impact on quality of life.
- Conditions
- Vulvar Atrophy, Vulvovaginal Signs and Symptoms, Genitourinary Syndrome of Menopause (GSM), Quality of Life
- Trial name
- NCT07737782
- Where
- Spain
- Volunteers
- 100 people
- Sponsor
- Mucosa Innovations, S.L.
Coronary Heart Disease
TAXUS® Element™ Paclitaxel-Eluting Coronary Stent System European Post-Approval Surveillance Study (TE-Prove)
The goal of the TAXUS™ Element™ Paclitaxel-Eluting Coronary Stent System European Post-Approval Surveillance Study is to evaluate real world clinical outcomes data for the TAXUS™ Element™ Coronary Stent System in unselected…
- Trial name
- TE-Prove (NCT01242696)
- Testing
- Coronary artery stenting
- Where
- 37 sites in Belgium, France and 8 more
- Volunteers
- 1,014 people
- Sponsor
- Boston Scientific Corporation
Psoriasis
A Real World Study Evaluating the Long-Term Quality of Life of Tildrakizumab in Adult Patients With Psoriasis
This is a Phase 4 multicenter, uncontrolled open-label study design. There will be a total of 10 study visits at Screening, Baseline, Week 4, Week 8, Week 12, Week 16, Week 28, Week 40, Week 52 and Week 64, with subjects…
- Trial name
- NCT03718299
- Testing
- Injections of tildrakizumab
- Where
- 2 sites in United States
- Volunteers
- 55 people
- Sponsor
- Sun Pharmaceutical Industries Limited
Diabetes Mellitus, Type 2
China Research of IDEgAsp Treatment in Real-world Clinical practicE (CREATE)
The purpose of this study is to collect information on how Ryzodeg® works in real-world patients. Participants will get Ryzodeg® as prescribed to by their doctor. The study will last for about 5-8 months.
- Trial name
- CREATE (NCT05221580)
- Testing
- Ryzodeg®
- Where
- 50 sites in China
- Volunteers
- 887 people
- Sponsor
- Novo Nordisk A/S
Migraine
Real World Effectiveness of Eptinezumab in Participants With Migraine
The purpose of this study is to examine how eptinezumab compares to other advanced preventive medications in a real-world community setting in adult participants with episodic migraine (EM) or chronic migraine (CM).
- Trial name
- EVEC (NCT05284019)
- Testing
- Eptinezumab, Erenumab, Onabotulinumtoxin-A
- Where
- 10 sites in United States
- Volunteers
- 32 people
- Sponsor
- H. Lundbeck A/S
Hyperphosphatemia
Multicenter, Open, Prospective, 48 Weeks, Observational Study ,Evaluate the Safety and Efficacy of Nephoxil Capsule
The purpose of this study is to evaluate the safety and efficacy of Nephoxil capsule administration for the improvement of hyperphosphatemia in CKD patients undergoing hemodialysis under actual conditions of routine medical care.
- Trial name
- NCT06206135
- Testing
- the low-dose group (1.5 g/day) or the standard-dose group (4 g/day)
- Where
- South Korea
- Volunteers
- 172 people, healthy volunteers welcome
- Sponsor
- LG Chem
Metastatic Castration Sensitive Prostate Cancer (mCSPC)
A Study to Learn About the Outcomes Between Study Medicines, Enzalutamide and Darolutamide Among Men With Metastatic Castration Sensitive Prostate Cancer (mCSPC)
The purpose of this real-world study of electronic medical records is to look back to compare the time to next treatment after initial treatment with enzalutamide or darolutamide in addition to androgen deprivation therapy (ADT).
- Trial name
- NCT07779590
- Testing
- darolutamide plus androgen deprivation therapy, Enzalutamide plus androgen deprivation therapy
- Where
- United States
- Volunteers
- 4,700 people
- Sponsor
- Pfizer
Diabetes Mellitus, Type 2
Real-world Study Comparing the Adherence and Effectiveness of Linagliptin vs. Acarbose
Non-interventional cohort study based on newly collected data under routine medical practice of a total of 500 Diabetes Mellitus, Type 2 patients
- Trial name
- NCT04180813
- Testing
- Linagliptin, Acarbose
- Where
- 10 sites in China
- Volunteers
- 85 people
- Sponsor
- Boehringer Ingelheim
Diabetes Mellitus, Type 2
A Research Study Looking at How Oral Semaglutide Works in People With Type 2 Diabetes in the United Kingdom, as Part of Local Clinical Practice
The purpose of the study is to collect information on how Rybelsus® works in people with type 2 diabetes and to see if Rybelsus® can lower their blood sugar levels.
- Trial name
- PIONEER REAL (NCT04862923)
- Testing
- Oral semaglutide
- Where
- United Kingdom
- Volunteers
- 336 people
- Sponsor
- Novo Nordisk A/S
Aphakia
A Real-World Evidence (RWE) Long-Term Follow-Up Study to Assess Outcomes of Alcon Monofocal Intraocular Lenses
The purpose of this post-market clinical follow-up (PMCF) study is to describe the long-term safety and performance of AcrySof Single-Piece and AcrySof Multi-Piece monofocal intraocular lenses (IOLs).
- Trial name
- NCT05799950
- Testing
- AcrySof single-piece IOL, AcrySof multi-piece IOL
- Where
- 7 sites in United States, Puerto Rico
- Volunteers
- 138 people
- Sponsor
- Alcon Research
Relapsing-Remitting Multiple Sclerosis (RRMS)
A Study for Tysabri Participant Preference
The primary objective of this study is to collect, evaluate and compare data on participant preference between subcutaneous (SC) and intravenous (IV) natalizumab.
- Trial name
- NCT05304520
- Testing
- Natalizumab
- Where
- 40 sites in Germany
- Volunteers
- 318 people
- Sponsor
- Biogen
Heart Failure With Reduced Ejection Fraction
A Real-world Study of Clinical Treatment Guidelines for Patients With Heart Failure With Reduced Ejection Fraction Treated With Sacubitril/Valsartan
The aim of this study was to describe the real-world clinical profile, treatment patterns, and guideline alignment of patients with heart failure with reduced ejection fraction (HFrEF) treated with sacubitril/valsartan in routine…
- Trial name
- REACT-HFrEF-RO (NCT07465679)
- Where
- Romania
- Volunteers
- 2,508 people
- Sponsor
- Novartis Pharmaceuticals
Philadelphia Chromosome-positive Chronic Myeloid Leukemia in Chronic Phase
Effectiveness and Safety Study of Generic Imatinib in Chronic Myeloid Leukemia Patients in Egypt
The purpose of this observational study is to evaluate the effectiveness and safety of generic imatinib under usual clinical practice in patients of Philadelphia chromosome-positive (Ph+) chronic myeloid leukemia (CML) patients…
- Trial name
- NCT03454503
- Testing
- Imatinib
- Where
- Egypt
- Volunteers
- 173 people
- Sponsor
- Hikma Pharmaceuticals LLC
Turner Syndrome
A Real-world Study of Long-acting Growth Hormone Injection for Turner Syndrome
This study is divided into two parts: Part A: A multicenter, retrospective, observational study to evaluate the effectiveness of PEG-rhGH in the treatment of Turner syndrome with domestic real-world data on rhGH as external…
- Trial name
- NCT06722079
- Where
- China
- Volunteers
- 743 people
- Sponsor
- Changchun GeneScience Pharmaceutical Co., Ltd.
Severe Aortic Stenosis
CoreValve Advance International Post Market Study
The CoreValve Advance study is intended to evaluate the clinical utility of the Medtronic CoreValve System in a "Real-World" patient population.
- Trial name
- NCT01074658
- Testing
- Medtronic CoreValve System
- Where
- 44 sites in Belgium, Colombia and 10 more
- Volunteers
- 1,015 people
- Sponsor
- Medtronic Cardiac Rhythm and Heart Failure
Chronic Pain
Algovita Post-Market Clinical Study: Spinal Cord Stimulation to Treat Chronic Pain
The purpose of this study is to obtain real-world clinical outcome data for the Algovita Spinal Cord Stimulation system when used, on-label, according to the applicable directions for use.
- Trial name
- NCT02373540
- Testing
- Algovita Spinal Cord Stimulation system
- Where
- 18 sites in United States, Germany
- Volunteers
- 91 people
- Sponsor
- Nuvectra
Chronic Kidney Disease
A Prospecitve Multicenter, Observational Registry Study
This is a prospective, multicenter, observational registry study designed to collect data to deepen the understanding of CKD therapeutics, changes in clinical practice, cardiorenal risk outcomes and differences in treatment…
- Trial name
- NCT07481526
- Where
- 59 sites in China
- Volunteers
- 3,000 people
- Sponsor
- AstraZeneca
Atrial Fibrillation
Edoxaban Treatment in Routine Clinical Practice for Patients With Non-valvular Atrial Fibrillation (ETNA-AF-Hong Kong)
In order to understand the risks and benefits of edoxaban use in a real-world clinical setting in the NVAF indication, Daiichi-Sankyo Hong Kong proposed this non-interventional study (NIS) to gain insight into the safety of…
- Trial name
- NCT03247582
- Testing
- Edoxaban
- Where
- 4 sites in Hong Kong
- Volunteers
- 234 people
- Sponsor
- Daiichi Sankyo Hong Kong Ltd., a Daiichi Sankyo Company
Coronary Artery Disease, Clopidogrel Resistance
The Study of CYP2C19 Genotype-Guided Clopidogrel Treatment Models
The study purposed to learn how clopidogrel-based antiplatelet treatment for preventing adverse cardiovascular events after ePCI works in chronic coronary artery disease when guided by personal genetic characteristics for drug…
- Conditions
- Coronary Artery Disease, Clopidogrel Resistance, Coronary Thrombosis, Adverse Cardiac Events
- Trial name
- NCT06665919
- Testing
- CYP2C19 Genotype-Guided Clopidogrel Treatment, CYP2C19 Genotype Guided Antiplatelet Treatment Alternative to Clopidogrel, The Conventional Clopidogrel Treatment
- Where
- 4 sites in Georgia
- Volunteers
- 283 people
- Sponsor
- Vistamedi Ltd.
The first 1,020 results can be paged through. Add a filter or change the sort order to reach the rest.